Fas and Fas ligand as prognostic factors in human breast carcinoma

Medical Science Monitor

Volumn 12, Issue 11, 2006, Pages

  Bȩbenek, Marek ^a   Dú, Danuta ^b   Koźlak, Joanna ^b  

^a Wroclaw   (Poland)

^b INSTITUTE OF IMMUNOLOGY AND EXPERIMENTAL THERAPY   (Poland)

Author keywords

Breast cancer; Fas; FasL; Prognosis

Indexed keywords

FAS ANTIGEN; FAS LIGAND;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PROGNOSIS; PROTEIN EXPRESSION;

ADULT; AGED; ANTIGENS, CD95; BREAST NEOPLASMS; CARCINOMA; FAS LIGAND PROTEIN; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; PHENOTYPE; PROGNOSIS; RECEPTORS, ESTROGEN; TIME FACTORS;

EID: 33750964747     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Parkin DM: Global cancer statistics in the year 2000. Lancet Oncol, 2001; 2: 533-43
2. Lutz JM, Francisci S, Mugno E et al: Cancer prevalence in Central Europe: the EUROPREVAL Study. Ann Oncol, 2003; 14: 313-22
3. Jezierska A, Olszewski WP, Pietruszkiewicz J et al: Activated Leukocyte Cell Adhesion Molecule (ALCAM) is associated with suppression of breast cancer cells invasion. Med Sci Monit, 2006; 12(7): BR245-56
4. Tot T: The limited prognostic value of measuring and grading small invasive breast carcinomas: The whole sick lobe versus the details within it. Med Sci Monit, 2006; 12(8): RA170-75
5. Itoh N, Yonehara S, Ishii A et al: The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell, 1991; 66: 233-43
6. Mottolese M, Buglioni S, Bracalenti C et al: Prognostic relevance of altered Fas (CD95)-system in human breast cancer. Int J Cancer, 2000; 89: 127-32
7. Muschen M, Moers C, Warskulat U et al: CD95 ligand expression as a mechanism of immune escape in breast cancer. Immunology, 2000; 99: 69-77
8. Nagata S: Apoptosis by death factor. Cell, 1997; 88: 355-65
9. O'Connell J, O'Sullivan GC, Collins JK, Shanahan F: The Fas counter-attack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J Exp Med, 1996; 184: 1075-82
10. Reimer T, Herrnring C, Koczan D et al: FasL: Fas ratio - a prognostic factor in breast carcinomas. Cancer Res, 2000; 60: 822-28
11. Reimer T, Koczan D, Muller H et al: Tumour Fas ligand: Fas ratio greater than 1 is an independent marker of relative resistance to tamoxifen therapy in hormone receptor positive breast cancer. Breast Cancer Res, 2000; 4: R9
12. Timmer T, de Vries EG, de Jong S: Fas receptor-mediated apoptosis: a clinical application? J Pathol, 2002; 196: 125-34
13. Yakirevich E, Maroun L, Cohen O et al: Apoptosis, proliferation, and Fas (APO-1, CD95)/Fas ligand expression in medullary carcinoma of the breast. J Pathol, 2000; 192: 166-73
14. Reed JC: Mechanisms of apoptosis. Am J Pathol, 2000; 157: 1415-30
15. Thorburn A: Death receptor-induced cell killing. Cell Signal, 2004; 16: 139-44
16. Rossi D, Gaidano G: Messengers of cell death: apoptotic signaling in health and disease. Haematologica, 2003; 88: 212-18
17. Nagata S, Golstein P: The Fas death factor. Science, 1995; 267: 1449-56
18. Bernstorff WV, Glickman JN, Odze RD et al: Fas (CD95/APO-1) and Fas ligand expression in normal pancreas and pancreatic tumors. Implications for immune privilege and immune escape. Cancer, 2002; 94: 2552-60
19. Botti C, Buglioni S, Benevolo M et al: Altered expression of FAS system is related to adverse clinical outcome in stage I-II breast cancer patients treated with adjuvant anthracycline-based chemotherapy. Clin Cancer Res, 2004; 10: 1360-65
20. Moller P, Koretz K, Leithauser F et al: Expression of APO-1 (CD95), a member of the NGF/TNF receptor superfamily, in normal and neoplastic colon epithelium. Int J Cancer, 1994; 57: 371-77
21. Nagarkatti N, Davis BA: Tamoxifen induces apoptosis in Fas+ tumor cells by upregulating the expression of Fas ligand. Cancer Chemother Pharmacol, 2003; 51: 284-90
22. Ragnarsson GB, Mikaelsdottir EK, Vidarsson H et al: Intracellular Fas ligand in normal and malignant breast epithelium does not induce apoptosis in Fas-sensitive cells. Br J Cancer, 2000; 83: 1715-21
23. Shiraki K, Naoki T, Isselbacher KJ, Takahashi H: Expression of Fas ligand in liver metastases of human colonic adenocarcinomas. Proc Natl Acad Sci, 1997; 94: 6420-25
24. Sjostrom J, Blomqvist C, von Boguslawski K et al: The predictive value of bcl-2, bax, bcl-xL, bag-1, fas, and fasL for chemotherapy response in advanced breast cancer. Clin Cancer Res, 2002; 8: 811-16
25. Ueno T, Toi M, Tominaga T: Circulating soluble Fas concentration in breast cancer patients. Clin Cancer Res, 1999; 5: 3529-33
26. Mann B, Gratchev A, Bohm C et al: FasL is more frequently expressed in liver metastases of colorectal cancer than in matched primary carcinomas. Br J Cancer, 1999; 79: 1262-69
27. Hahne M, Rimoldi D, Schroter M et al: Melanoma cell expression of Fas (APO-1/CD95) ligand: implications for tumor immune escape. Science, 1996; 274: 1363-66
28. O'Connell J, Bennett MW, O'Sullivan GC et al: Expression of Fas (CD95/APO-1) ligand by human breast cancers: significance for tumor immune privilege. Clin Diagn Lab Immunol, 1999; 6: 457-63
29. Keane MM, Ettenberg SA, Lowrey GA et al: Fas expression and function in normal and malignant breast cell lines. Cancer Res, 1996; 56: 4791-98
30. Hayes DF: Do we need prognostic factors in nodal-negative breast cancer? Arbiter. Eur J Cancer, 2000; 36: 302-6
31. Kaufmann M, Scharl A: Do we need better prognostic factors in nodal-negative breast cancer? Contra. Eur J Cancer, 2000; 36: 298-301
32. Thomssen C, Janicke F: Do we need better prognostic factors in node-negative breast cancer? Pro. Eur J Cancer, 2000; 36: 293-98